Jaipur, India — Rajasthan’s Health Minister, Gajendra Singh Khimsar, addressed the state assembly on Tuesday regarding the troubling allegations surrounding cough syrup consumption linked to the deaths of several children. He emphasized that neither the government nor the medical community could be held accountable for these incidents, as the syrup in question was given to children without professional medical advice.
During the Assembly’s Question Hour, Khimsar responded to inquiries regarding possible collusion between state officials and a pharmaceutical company that supplied the cough syrup. These concerns emerged following a series of mysterious childhood fatalities reported in October 2025. The minister stated that accountability would arise only when medications are prescribed by medical professionals.
“If a doctor prescribes a medicine and it causes harm, the responsibility lies with the healthcare provider and the government. However, when parents administer medication without consulting a medical expert, those parties cannot be held liable,” Khimsar articulated. He highlighted that the reported instances related to the syrup were confined to just a few cases — estimating between two and five deaths.
Khimsar pointed out that the syrup contains ingredients such as codeine and claimed that the deaths were a result of overdosing rather than any fault in the product itself. “These tragic outcomes are largely due to improper usage rather than defects in the medication,” he asserted.
His comments sparked opposition from various assembly members. Leader of the Opposition, Tikaram Jully, contested Khimsar’s statements. He accused the government of negligence and said the company involved in supplying the syrup had been blacklisted in multiple regions. Jully challenged the minister’s position that the syrup has been safely used since the Congress regime, arguing that acknowledging deaths related to overdose implies a serious concern regarding the drug’s administration.
Moreover, Jully raised questions about the quality of the syrup over time, suggesting that while it may have been safe initially, it could have deteriorated in quality at later stages. The controversy surrounding the cough syrup has intensified scrutiny of pharmaceutical practices in the state, and parents are demanding answers and accountability as the investigation continues.
With the implications of these events remaining significant, many locals hope for a thorough examination of the product’s safety and the regulatory frameworks governing its distribution. The Assembly discussions underscore ongoing concerns regarding the intersection of healthcare, regulation, and public safety, leaving many community members anxious for clarity and resolution.